Results 151 to 160 of about 957,553 (357)

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Unlocking the power of precision medicine for pediatric low-grade gliomas: molecular characterization for targeted therapies with enhanced safety and efficacy [PDF]

, 2023
Selene Cipri, Giada Del Baldo, Francesco Fabozzi, Luigi Boccuto, Andrea Carai, Angela Mastronuzzi   +5 more
openalex   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Development of a biomimetic nanoparticle platform for apigenin therapy in triple-negative breast cancer

Frontiers in Oncology
BackgroundThis study investigates the therapeutic potential and mechanisms of Apigenin (AGN) in treating triple-negative breast cancer (TNBC). Although AGN is recognized for its anti-tumor properties, its specific mechanisms in TNBC remain unclear ...
Chenyang Wang, Chenyang Wang, Chenyang Wang, Xiaojing Ren, Xiaojing Ren, Xiaojing Ren, Yanmei Han, Yanmei Han, Yanmei Han, Ding Nan, Ding Nan, Ding Nan, Yajing Zhang, Yajing Zhang, Yajing Zhang, Zairong Gao, Zairong Gao, Zairong Gao   +17 more
doaj   +1 more source

Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma. [PDF]

Curr Oncol, 2023
Kumar S, Pandey AK.
europepmc   +1 more source

Data from Nanobodies Targeting the Hepatocyte Growth Factor: Potential New Drugs for Molecular Cancer Therapy

, 2023
Maria J.W.D. Vosjan, Jo Vercammen, Joost A. Kolkman, Marijke Stigter‐van Walsum, Hilde Revets, Guus A.M.S. van Dongen   +5 more
openalex   +1 more source

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

Molecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande, Marcela de Oliveira Silva, Mariana Bisarro dos Reis, Rodrigo de Oliveira Cavagna, Luciane Sussuchi, Icaro Alves Pinto, Natalia Zampieri Pontes, Rodrigo Sampaio Chiarantano, Flavio Augusto Ferreira da Silva, Pedro de Marchi, Letícia Ferro Leal, Rui M. Reis   +11 more
wiley   +1 more source

Molecular targeted therapy: A new avenue in glioblastoma treatment. [PDF]

Oncol Lett, 2023
El Atat O, Naser R, Abdelkhalek M, Habib RA, El Sibai M.   +4 more
europepmc   +1 more source

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source

Advantages of the Combinatorial Molecular Targeted Therapy of Head and Neck Cancer-A Step before Anakoinosis-Based Personalized Treatment. [PDF]

Cancers (Basel), 2023
Kleszcz R.
europepmc   +1 more source